Table 1.

Details of subject characteristics, dose, and clinical responses

IDAge*Sex (M/F, 5/7)Stage (III, 2; IV, 10)Disease sitesPrior therapyDose levelTotal dendritic cell doseOutcome
10172FIVSoft tissues, mesenterySurgery130 × 106SD
10249FIVDistant lymph nodesSurgery, IFN130 × 106SD Now NED
10355MIVSoft tissue, lung, mesenterySurgery, XRT, chemotherapy130 × 106Twice§ PR; then PD
20169MIVLymph node, lung, liverSurgery, XRT290 × 106PD
20251FIVSkin, soft tissue, adrenalSurgery, IFN290 × 106PD
20329FIIISkinSurgery, IFN290 × 106PD now NED
30167MIVLungSurgery3250 × 106PD
30275MIIISkinSurgery, IFN3300 × 106PR
30359MIVSkin, lung, liver, brainSurgery, XRT3300 × 106PD
30471MIVLiverNone3300 × 106SD; then PR AWD
30560MIVAbdominal massSurgery, IFN3300 × 106PD
30650FIVLungSurgery, chemotherapy3200 × 106PD
  • Abbreviations: PD, progressive disease; SD, stable disease; PR, partial response; NED, no evidence of disease; AWD, alive with disease; XRT, radiation therapy.

  • * Median age, 59.5; range, 29-75.

  • Five men, seven women.

  • Dose level 1: 10 × 106: 2, 15 × 106: 3, 50 × 106.

  • § Subject 103 experienced a PR, underwent a second course of therapy, and then progressed.

  • Subject 304 showed stable disease after six treatments but went on to experience a partial response 4.5 months after the last treatment without additional therapy.